The U.S. Court of Appeals for the Federal Circuit renders a split decision regarding sham patent litigation (Tyco Healthcare / Mutual Pharmaceutical)

The U.S. Court of Appeals for the Federal Circuit has remanded for further consideration antitrust claims accusing a patent holder of filing a sham infringement suit and a sham citizen petition with the Federal Drug Administration. The case is Tyco Healthcare Group LP v. Mutual Pharmaceutical Co. (Fed. Cir., Aug. 6, 2014). This split decision has significant implications both for patent holders planning to assert infringement claims and for infringement defendants considering antitrust counterclaims. Background Sandoz Limited applied for several patents directed to formulations and features of, and methods of treatment with, temazepam, a drug used to treat insomnia. In 2001, Tyco Healthcare Group LP and Mallinckrodt, Inc. ("Tyco") acquired the patents from Sandoz, and currently

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Geoffrey D. Oliver, Michelle K. Fischer, Kevin D. McDonald, The U.S. Court of Appeals for the Federal Circuit renders a split decision regarding sham patent litigation (Tyco Healthcare / Mutual Pharmaceutical), 6 août 2014, e-Competitions August 2014, Art. N° 68720

Visites 131

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues